Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat
Paraules clau
Resum
Descripció
Gamma-hydroxybutyric acid (GHB) is an endogenous compound present in most mammalian tissues at nanomolar concentrations and a minor metabolite or precursor of gammaaminobutyric acid (GABA). GHB was first synthesized in 1960 by the French biochemist H.-M. Laborit who was searching for analogues of GABA. Currently, medically formulated GHB sodium oxybate (Xyrem®) is approved in different countries for such varied uses as general anaesthesia, the treatment of alcohol withdrawal and addiction, and cataplexy associated with narcolepsy.
Pharmacokinetics of GHB are characterized by rapid oral absorption, with peak concentrations in plasma 20-45 min after dosing, and half-life of 20-30 min. The majority of the dose is eliminated completely within 4-8 h. Metabolism of GHB occurs via GHB dehydrogenase, which transforms it into succinic semialdehyde and, by a second oxidation step with transformation into succinic acid, it is then ultimately metabolized to water and excreted through breath as carbon dioxide. However, GHB exposure is increased in patients with liver function impairment and has been suggested presystemic (hepatic first pass) metabolism mediated by the CYP450 system in humans.
During the 1980s, easy access to GHB-containing products led to various unapproved uses, including weight loss, bodybuilding and the treatment of sleeplessness, sometimes with serious long-term effects. During the last years, GHB has become a major concern in emergency rooms of some countries due to an important increase in the number of cases of intoxications.
Since the drug is both inexpensive and easy to ingest, it has been popular as a "party drug." The calming and euphoric effects of GHB in low doses (20-30 mg/kg) have given the drug the nickname "liquid ecstasy". At higher doses (> 50 mg/kg), the hypnotic effects are more prominent and at doses >60 mg/kg coma, convulsions, and respiratory depression can occur. The clinical hallmark of GHB poisoning is rapid onset of coma, with respiratory depression, hypoventilation and bradycardia. Combination with alcohol potentiates these effects, especially respiratory depression and hypotension.
Regular use of GHB is thought to be relatively higher in the lesbian, gay, bisexual, and transgender community. Anecdotal evidence suggests that GHB use is increasing and this may be driven in part by an increase in the incidence of chemsex. Chemsex is a specific form of recreational drug use involving specific drugs such as GHB/γ-butyrolactone (GBL), methylamphetamine and mephedrone, alone or in combination, to enhance or prolong sexual sessions. Such sessions can last for several days, involve multiple partners and include high risk behaviour.
Although the phenomenon of chemsex was initially limited to the metropolitan area of London, it is getting spread across other big European cities, making of this an emerging global health issue. Chemsex is especially common among men who have sex with other men (MSM) and in people living with HIV (PLWH), with up to 50% of HIV-positive MSM reporting to be engaged in chemsex in recent months.
Consumption of recreational drugs in PLWH has been associated with high-risk practices for sexually transmitted diseases. In addition, use of drugs in patients taking antiretroviral therapy (ART) might result in pharmacological interactions with potential risk of overdosing. Noteworthy, widespread use of chemsex drugs has resulted in increased rates of overdose and associated deaths, and Handley & Flanagan have reported an increase in the number of cases of fatal poisoning with GHB, mephedrone and ketamine in England and Wales since 2008. Also, GHB-associated deaths have been reported from the USA, Canada, Europe and Australia.
Cobicistat (GS-9350) is a pharmacokinetic enhancer that was developed to inhibit CYP3A activity in a time- and concentration-dependent manner, thus boosting other antiretroviral drugs. Results from clinical trials showed that it can increase the plasma exposure of elvitegravir, atazanavir, and darunavir. Similarly, cobicistat increases the exposure to many other xenobiotics. For example, it is well known that CYP3A4 inhibition leads to a significant increase in concentrations of sildenafil and other erectile dysfunction agents, and that a dose adjustment is needed in this scenario. Similarly, CYP3A4 inhibition increased ketamine exposure in a small clinical trial in healthy volunteers.
There are two case reports in the literature of well documented life-threatening overdoses on GHB and MDMA in HIV-positive patients on treatment with high-doses of ritonavir (600 mg bid). However, the possibility for this drug interaction with the low doses of pharmacoenhancers currently used (ritonavir 100 mg qd, cobicistat 150 mg qd) is still a matter for debate, Despite data suggesting the possibility of drug interactions between cobicistat and GHB, formal pharmacokinetic studies assessing this issue are lacking.
Dates
| Darrera verificació: | 06/30/2020 |
| Primer enviat: | 12/09/2019 |
| Inscripció estimada enviada: | 03/24/2020 |
| Publicat per primera vegada: | 03/25/2020 |
| Última actualització enviada: | 07/20/2020 |
| Publicació de l'última actualització: | 07/21/2020 |
| Data d'inici de l'estudi real: | 01/29/2020 |
| Data estimada de finalització primària: | 03/29/2020 |
| Data estimada de finalització de l’estudi: | 04/29/2020 |
Condició o malaltia
Intervenció / tractament
Drug: Cobicistat 150 MG
Drug: Placebo
Drug: GHB
Fase
Grups de braços
| Braç | Intervenció / tractament |
|---|---|
| Experimental: COBI period (5 days) + Placebo period (5 days) volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB | |
| Experimental: Placebo period (5 days) + COBI period (5 days) volunteers will receive once-daily placebo for 5 days. On day 5, participants will receive a single oral dose of GHB. After a washout period for 7 days, volunteers will receive once daily cobicistat for 5 days. On day 5, participants will receive a single oral dose of GHB. |
Criteris d'elegibilitat
| Edats elegibles per estudiar | 18 Years Per a 18 Years |
| Sexes elegibles per estudiar | All |
| Accepta voluntaris saludables | Sí |
| Criteris | Inclusion Criteria: 1. Males and females* aging 18-45 years. 2. Body weight ranging between 50 and 100 Kg. 3. Previous experience with the consumption of sedatives (alcohol, cannabis, benzodiazepines, GHB or other hypnotics). 4. Absence of abnormalities in the screening ECG and blood/urine tests. 5. Agree with the study procedures and signature of the informed consent. - Women of childbearing potential must have a negative pregnancy test prior to randomization into the study and commitment to use at least one of these birth control methods: male or female condom with or without spermicide, cap, diaphragm or sponge with or without spermicide, intrauterine device, bilateral tubal occlusion, vasectomized partner, sexual abstinence during the study. Condom use is considered as an additional method of contraception only and cannot be the only method of contraception used as not been considered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines. Based on ICH, M3 (R2) 2009 a woman is considered of childbearing potential: fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include tubal ligation, hysterectomy, bilateral oophorectomy. Exclusion Criteria: 1. Prior history of medical or psychiatric adverse reaction following GHB consumption. 2. Current substance use disorder (DSM-V, dependence, addiction) of any drug or substance of abuse. 3. Prior history of substance use disorder (DSM-V, drug use disorder or addiction) of any drug or substance of abuse (except nicotine). 4. Smokers>10 cigarettes/day. 5. History of any physical condition or major surgery within the previous three months. 6. History of individual psychiatric conditions or schizophrenia in first-degree relatives. 7. History of gastrointestinal, hepatic, renal diseases or other conditions which, in opinion of the investigator, may affect drug absorption, distribution, metabolism or elimination. 8. Alcohol intake higher than 4 units/day (40 g) in men or 2 units/day (20 g) in women. 9. Positive urine drug test (Amphetamines, Barbiturates, Benzodiazepines, Cocaine, MDMA, Methamphetamine, Morphine/Opioids, Methadone, tricyclic antidepressants, THC) 10. HIV infection, chronic hepatitis C (IgG VHC) or B (HBsAg). 11. Lactose intolerance 12. Pregnancy, lactation, or planned pregnancy during the study period. 13. Current or recent pharmacological treatment (≥3 doses per week) in the last 2 weeks 14. Blood donation in the 3 previous months 15. Participation in another clinical trial in the previous 3 months |
Resultat
Mesures de resultats primaris
1. concentration in plasma of GHB [days 5 and 17]
2. Proportion of participants reporting adverse events. [Since baseline to day 28]
Mesures de resultats secundaris
1. physiological effects: blood pressure [days 5 and 17]
2. physiological effects: heart rate [days 5 and 17]
3. physiological effects : oxygen saturation [days 5 and 17]
4. subjective effects of GHB -ARCI [days 5 and 17]
5. subjective effects of GHB - Visual analog scale [days 5 and 17]
